Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported that the last patient has completed the final clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping topline data on track for September 2026.

CANYON-1 is a 16‑week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adults in the U.S., testing once-daily oral doses of 20 mg, 40 mg and 60 mg versus placebo with a dose-titration regimen and a 4‑week safety follow-up. CRB-913 is described as a highly peripherally restricted CB1 inverse agonist, aiming to offer an orthogonal, non-incretin oral approach to weight loss. The study follows Phase 1a data indicating differentiated GI tolerability versus GLP‑1 therapies and preclinical mouse data showing approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant.

Positive

• CANYON-1 Phase 1b reached Last Patient Last Visit, enabling planned September 2026 topline data
• 240-patient randomized, double-blind, placebo-controlled obesity study completed dosing and follow-up
• Dose-ranging design evaluates 20 mg, 40 mg, 60 mg once-daily CRB-913 with titration
• Phase 1a SAD/MAD data showed differentiated GI tolerability versus GLP-1 class
• Preclinical mouse data showed 15x lower brain penetration for CRB-913 versus monlunabant

Negative

• None.

Market Context

Recent insider activity was labeled Net Buying, with 13,500 shares bought and 9,238 sold. That conte...

Analysis

Recent insider activity was labeled Net Buying, with 13,500 shares bought and 9,238 sold. That context frames CANYON-1 completion as a milestone awaiting September readout, with safety and efficacy still unresolved.

Key Figures

Study size: 240 participants Topline readout: September 2026 Brain penetration: 15 times lower +5 more

8 metrics

Study size 240 participants CANYON-1 Phase 1b study

Topline readout September 2026 CANYON-1 study

Brain penetration 15 times lower CRB-913 versus monlunabant in mice

Study duration 16 weeks Double-blind, placebo-controlled CANYON-1 trial

Dose cohorts 20 mg, 40 mg, and 60 mg Once-daily CRB-913 cohorts

Dosing period 12 weeks Participant dosing period

Safety follow-up 4 weeks Post-dosing safety follow-up

Incretin discontinuation Over 60% People discontinuing therapy in their first year

Historical Context

5 past events · Latest: Jul 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 28	FDA clearance	Positive	+0.1%	FDA cleared initiation of the registrational TEMPO-1 CRB-701 study
Jul 06	Leadership appointment	Neutral	-2.7%	Leonardo Viana Nicacio was appointed chief medical officer
May 26	Clinical data	Positive	-30.3%	Updated CRB-701 data reported response rates in two cancer indications
May 21	Conference scheduling	Positive	+18.3%	Company scheduled a CRB-701 data call and highlighted summer milestones
May 14	Board appointment	Neutral	-1.4%	Brent Pfeiffenberger joined the board as Corbus advanced pipeline programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed mixed reactions, including a -30.31% 24-hour move after positive CRB-701 clinical data.

Key Terms

last patient last visit, cb1 inverse agonist, double-blind, placebo-controlled, +1 more

5 terms

last patient last visit medical

"the last patient has completed their last clinical visit"

The point when the final study participant completes their final scheduled clinical visit, marking the end of active data collection for that trial. It matters to investors because it signals that the sponsor can lock and analyze trial data, move toward regulatory filings or public results, and set clearer timelines for potential approvals or commercial milestones—like the last puzzle piece being placed before you can see the full picture.

cb1 inverse agonist medical

"a once-daily highly peripherally restricted oral CB1 inverse agonist"

A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.

double-blind medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

dose-ranging medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Dose-finding Phase 1b study (n=240) on track for topline data in September 2026
• CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 class
• CRB-913 yielded 15 times lower brain penetration than monlunabant in mice
  
  

NORWOOD, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical visit (“Last Patient Last Visit”) in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track for topline data readout in September 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP-1 and other incretin-targeting therapies.

The CANYON-1 Phase 1b clinical trial is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States (NCT07310901). The trial includes three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD) as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was included in the design, with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their assigned cohorts. Participants were dosed for 12-weeks followed by a four-week safety follow-up.

“Despite the remarkable success of GLP-1s and the incretin class, significant treatment gaps exist for people struggling with obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Over 60% of those who try incretin therapy discontinue it in their first year, often as a result of intolerance or lack of satisfactory response to this therapy. Our upcoming data readout of the CANYON-1 study will help further inform CRB-913's potential to deliver an orthogonal, oral, non-incretin therapeutic option for effective weight loss and sustained weight management. Importantly, CANYON-1 is expected to provide clarifying insights as to its safety and efficacy and allow us to contextualize the data in comparison to both oral GLP-1 agonists as well as the CB1 inverse agonist monlunabant.”

About the CRB-913 Phase 1a Study Findings
Corbus completed a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 in December 2025. The SAD portion of the trial enrolled 64 participants across 8 cohorts. The MAD portion enrolled 48 participants across 4 cohorts, including a dedicated obese cohort. The highest SAD dose tested was 600 mg/day, and the highest MAD dose tested was 150 mg/day. In the dedicated obese MAD cohort (150 mg/day), all CRB-913-treated participants (n=9), and none in the placebo group (n=3), experienced weight loss. The CRB-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Weight loss started early and deepened with time. CRB-913 was safe and well-tolerated across all cohorts and all doses studied, including demonstrating a very favorable GI profile with no reports of vomiting, constipation or nausea. Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including statements relating to the anticipated timing of topline data from the CANYON-1 study, the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, the potential of CRB-913 relative to GLP-1 and other incretin-targeting therapies and to monlunabant, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

What did Corbus Pharmaceuticals (CRBP) announce about the CANYON-1 study on August 4, 2026?

Corbus Pharmaceuticals announced that the CANYON-1 Phase 1b trial of CRB-913 reached Last Patient Last Visit, with topline data expected in September 2026. According to Corbus Pharmaceuticals, this milestone completes patient visits and supports upcoming safety and efficacy analyses in obesity.

What is the design of the CRB-913 CANYON-1 Phase 1b obesity trial for CRBP?

CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging Phase 1b study in 240 obese, non-diabetic adults. According to Corbus Pharmaceuticals, it tests once-daily 20 mg, 40 mg and 60 mg CRB-913 versus placebo, with 12 weeks of dosing and 4 weeks of safety follow-up.

When will Corbus Pharmaceuticals (CRBP) report topline data from the CANYON-1 CRB-913 trial?

Topline data from the CANYON-1 Phase 1b study of CRB-913 are expected in September 2026. According to Corbus Pharmaceuticals, completion of Last Patient Last Visit keeps the trial on track for this timing, pending data cleaning and analysis in obesity patients.

How does CRB-913 differ from GLP-1 obesity drugs for Corbus Pharmaceuticals (CRBP)?

CRB-913 is a peripherally restricted oral CB1 inverse agonist, offering a non-incretin mechanism distinct from GLP-1 drugs. According to Corbus Pharmaceuticals, Phase 1a data showed differentiated gastrointestinal tolerability compared with the GLP-1 class, potentially addressing treatment gaps in obesity management.

What dosing regimens are being tested for CRB-913 in the CANYON-1 study for CRBP?

CANYON-1 evaluates once-daily CRB-913 doses of 20 mg, 40 mg and 60 mg, alongside placebo in a 1:1:1:1 randomization. According to Corbus Pharmaceuticals, all active-treatment participants start at 20 mg and titrate up to their assigned target dose.

What preclinical safety-related data has Corbus (CRBP) reported for CRB-913 versus monlunabant?

In mouse studies, CRB-913 showed approximately 15 times lower brain penetration than the CB1 inverse agonist monlunabant. According to Corbus Pharmaceuticals, this peripherally restricted profile may be relevant to safety considerations, though it still requires confirmation in human clinical studies.

What patient population is enrolled in Corbus Pharmaceuticals' (CRBP) CANYON-1 CRB-913 obesity trial?

CANYON-1 enrolled 240 obese, non-diabetic adult participants at multiple U.S. clinical sites. According to Corbus Pharmaceuticals, these individuals received 12 weeks of once-daily oral CRB-913 or placebo, followed by a four-week safety follow-up period in the Phase 1b study.